Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept Therapy for the Failing Renal Allograft

Next Previous
Trial Profile

Belatacept Therapy for the Failing Renal Allograft

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use

Most Recent Events

  • 01 Dec 2021 Primary endpoint (Number of Participants With Donor-specific Antibody Formation) has been met, as per results published in the Transplantation.
  • 01 Dec 2021 Results assessing efficacy and safety of belatacept in kidney transplant recipients with failed allografts for the prevention of humoral sensitization, published in the Transplantation.
  • 08 Jan 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top